MRC urges hold on further health IT regulation until FDASIA report

The mHealth Regulatory Coalition (MRC) is urging Congress to hold off on passing legislation further regulating health IT until the Food and Drug Administration Safety and Innovation Act (FDASIA) workgroup releases its report.

The workgroup is set to present its report on a risk-based regulatory framework for health IT, which includes mobile health, sometime early this year.

In its approved policy proposal, MRC said premature legislation could thwart opportunities in the future to balance both public health protections and innovation.

“Protecting patients is of paramount importance here just as it is anywhere in healthcare. Patients come first. But we frankly see potential opportunities down the road, after these issues have percolated a bit, to both increase patient protections while simultaneously decreasing the regulatory burdens on those who innovate in this space, producing public health advancements,” according to the proposal.

MRC recommended several objectives that legislators should pursue when creating a new regulatory paradigm for health IT, including:

  • Collection of “good data” on health IT risks
  • Systems-level regulation that recognizes a future of health IT that is based on integrating technology
  • A nuanced categorization scheme that takes into account different risk factors of the elements of health IT systems
  • Utilization of private resources, such as notified bodies, to certify low risk medical technology
  • Encouragement of collaboration between IT vendors, researchers and end users

The policy proposal also created new terms to identify various elements within a health IT system and various roles and responsibilities of the organizations that manage those elements.  

 

 

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.